Anti-Porphyromonas gingivalis lipopolysaccharide antibody in rheumatoid arthritis patients with emphysema

Anti-<i>P. gingivalis</i> LPS Ab levels in RA with EMP were lower compared with RA without CLD. Citrullinated peptides were mainly generated in the lungs of RA with EMP and the oral cavity of RA without CLD, suggesting the heterogeneity of RA.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2025-09-22
DOI
https://doi.org/10.3389/fmed.2025.1654271
Citations
1
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
1.52

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Anti-Porphyromonas gingivalis lipopolysaccharide antibody in rheumatoid arthritis patients with emphysema

Shigeto Tohma, Takashi Higuchi, Kota Shimada, Norie Yoshikawa et al.
1 citations
Frontiers in Medicine
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
1.52
article

Anti-Porphyromonas gingivalis lipopolysaccharide antibody in rheumatoid arthritis patients with emphysema

Shigeto Tohma, Takashi Higuchi, Kota Shimada, Norie Yoshikawa, Kiyoshi Migita, Naoshi Fukui, Akiko Komiya, Hiroshi Furukawa, Atsushi Hashimoto, Misuzu Fujimori, Toshihiro Matsui, Koichiro Saisho, Shomi Oka, Michita Suzuki
article en
1 citations

Abstract

Anti-<i>P. gingivalis</i> LPS Ab levels in RA with EMP were lower compared with RA without CLD. Citrullinated peptides were mainly generated in the lungs of RA with EMP and the oral cavity of RA without CLD, suggesting the heterogeneity of RA.

Frontiers in MedicineVol. 12
Fukushima Medical University (JP), Tokyo University of the Arts (JP), National Sagamihara Hospital (JP), Nagasaki Medical Center (JP), Himeji Medical Center (JP), National Institute of Technology, Miyakonojo College (JP), Tokyo Metropolitan Tama Medical Center (JP), Nagoya Medical Center (JP), Sagami Chemical Research Institute (JP), Tokyo National Hospital (JP), The University of Tokyo (JP)
Bristol-Myers Squibb, Pfizer, Japan Research Foundation for Clinical Pharmacology, Nakatomi Foundation, Mitsui Sumitomo Insurance Welfare Foundation, Abbott Japan, Eisai, Astellas Pharma, Daiwa Securities Health Foundation, Teijin Pharma, Mitsubishi Tanabe Pharma Corporation, Pfizer Japan, Chugai Pharmaceutical, Japan Society for the Promotion of Science
Openalex Percentile: Top 14%
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.